<DOC>
	<DOCNO>NCT02551159</DOCNO>
	<brief_summary>This randomize , open-label , multi-center , 3-arm , global Phase III study determine efficacy safety MEDI4736 + tremelimumab combination MEDI4736 monotherapy versus SoC ( EXTREME regimen ) treatment patient SCCHN receive prior systemic chemotherapy recurrent metastatic disease .</brief_summary>
	<brief_title>Phase III Open Label Study MEDI 4736 With/Without Tremelimumab Versus Standard Care ( SOC ) Recurrent/Metastatic Head Neck Cancer</brief_title>
	<detailed_description>Patients randomize 2:1:1 ratio MEDI4736 + tremelimumab combination therapy , MEDI4736 monotherapy , SoC . Patients arm continue therapy progression . Tumor assessment perform computed tomography scan magnetic resonance imaging scan , preferably intravenous ( IV ) contrast . Efficacy patient assess objective tumor assessment every 6 week first 24 week , every 8 week thereafter treatment discontinuation due progression toxicity . All patient follow every 3 month survival progression confirm .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age â‰¥18 year time screen 2 . Documented evidence recurrent metastatic SCCHN ( oral cavity , oropharynx , hypopharynx , larynx ) . 3 . A fresh tumor biopsy purpose screen available archival tumor sample . Tumor lesion use fresh biopsy lesion use RECIST target lesion , unless lesion suitable biopsy . 4 . No prior systemic chemotherapy recurrent metastatic disease 5 . World Health Organization ( WHO ) /Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 enrollment 6 . No prior exposure immunemediated therapy , 1 . Histologically cytologically confirm head neck cancer primary anatomic location head neck specify inclusion criterion include patient SCCHN unknown primary nonsquamous histology ( eg , nasopharynx salivary gland ) 2 . Tumor progression recurrence within 6 month last dose platinum therapy primary treatment set 3 . Receipt radiotherapy hormonal therapy cancer treatment within 30 day prior first dose study treatment 4 . Active prior document autoimmune inflammatory disorder ( include inflammatory bowel disease [ eg , colitis , Crohn 's disease ] , diverticulitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>program cell death ligand 1 ( PD-L1 ) , MEDI4736 , Cytotoxic T-lymphocyte-associated antigen 4 { CTLA-4 } , PFS , SCCHN</keyword>
</DOC>